Display Settings:

Format

Send to:

Choose Destination

    Ann Gen Psychiatry. 2009 Jun 18;8:15.

    Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study.

    Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I.

    Janssen-Cilag Pharmaceutical SACI, Eirinis Avenue 56, 15121 Pefki, Athens, Greece. spapanic@jacgr.jnj.com.

    ABSTRACT: Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008, 7:16. This correction reports changes in the values listed for Ziprasidone and Aripiprazole in Table Ten.

    PMID: 19538726 [PubMed - in process]

    PMCID: PMC2705371

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Aripiprazole (Abilify®)

      Aripiprazole is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers 13 years of...

    • Ziprasidone (Geodon®)

      Ziprasidone is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). It is also used to treat episodes o...

    • Paliperidone (Invega®)

      Paliperidone is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Paliperidone is in a class of medi...